In Vivo Loss of Function Screening Reveals Carbonic Anhydrase IX as a Key Modulator of Tumor Initiating Potential in Primary Pancreatic Tumors

by Nabendu Pore, Sanjoo Jalla, Zheng Liu, Brandon Higgs, Claudio Sorio, Aldo Scarpa, Robert Hollingsworth, David A. Tice, Emil Michelotti
Published 2015-06-01

MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgro...

by Yoshimi Endo Greer, Samuel F. Gilbert, Brunilde Gril, Rajesh Narwal, Danielle L. Peacock Brooks, David A. Tice, Patricia S. Steeg, Stanley Lipkowitz
Published 2019-02-01

IL-6 Inhibition With MEDI5117 Decreases The Fraction of Head and Neck Cancer Stem Cells and Prevents Tumor Recurrence

by Kelsey A. Finkel, Kristy A. Warner, Samuel Kerk, Carol R. Bradford, Scott A. McLean, Mark E. Prince, Haihong Zhong, Elaine M. Hurt, Robert E. Hollingsworth, Max S. Wicha, David A. Tice, Jacques E. Nör
Published 2016-05-01

Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells

by Krishna Kalyan Kolluri, Constantine Alifrangis, Neelam Kumar, Yuki Ishii, Stacey Price, Magali Michaut, Steven Williams, Syd Barthorpe, Howard Lightfoot, Sara Busacca, Annabel Sharkey, Zhenqiang Yuan, Elizabeth K Sage, Sabarinath Vallath, John Le Quesne, David A Tice, Doraid Alrifai, Sylvia von Karstedt, Antonella Montinaro, Naomi Guppy, David A Waller, Apostolos Nakas, Robert Good, Alan Holmes, Henning Walczak, Dean A Fennell, Mathew Garnett, Francesco Iorio, Lodewyk Wessels, Ultan McDermott, Samuel M Janes
Published 2018-01-01